Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Reynolds

Showing results (201-210 of 212) with videos related to

Pageof 22
Sort By:
Pediatric Blood & Cancer|April 1, 2018
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Steven G DuBois, Araz Marachelian, et al.
Science Translational Medicine|November 19, 2025
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastomaAnna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
EMBO Molecular Medicine|May 18, 2013
ERBB4 confers metastatic capacity in Ewing sarcomaAriadna Mendoza-Naranjo, Amal El-Naggar, Daniel H Wai, et al.
Nature Communications|November 30, 2019
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M Trigg, Liam C Lee, Nina Prokoph, et al.
Pediatric Blood & Cancer|October 27, 2006
The pediatric preclinical testing program: description of models and early testing resultsPeter J Houghton, Christopher L Morton, Chandra Tucker, et al.
Pediatric Blood & Cancer|February 4, 2010
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conferenceTerzah M Horton, Richard Sposto, Patrick Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Nature Biomedical Engineering|April 7, 2019
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse modelsWalid S Kamoun, Dmitri B Kirpotin, Zhaohua Richard Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Pageof 22

Showing results (201-210 of 212) with videos related to

Sort By:
Pageof 22
Pediatric Blood & Cancer|April 1, 2018
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Steven G DuBois, Araz Marachelian, et al.
Science Translational Medicine|November 19, 2025
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastomaAnna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
EMBO Molecular Medicine|May 18, 2013
ERBB4 confers metastatic capacity in Ewing sarcomaAriadna Mendoza-Naranjo, Amal El-Naggar, Daniel H Wai, et al.
Nature Communications|November 30, 2019
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M Trigg, Liam C Lee, Nina Prokoph, et al.
Pediatric Blood & Cancer|October 27, 2006
The pediatric preclinical testing program: description of models and early testing resultsPeter J Houghton, Christopher L Morton, Chandra Tucker, et al.
Pediatric Blood & Cancer|February 4, 2010
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conferenceTerzah M Horton, Richard Sposto, Patrick Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Nature Biomedical Engineering|April 7, 2019
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse modelsWalid S Kamoun, Dmitri B Kirpotin, Zhaohua Richard Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Pageof 22